Scientific Publications

Advancing dermatological science.

March 2023

AAD 2023

Patient and Healthcare Provider Perspective on the Treatment Patterns and Patient Satisfaction of Seborrheic Dermatitis in the United States: Results from a National Survey
Read More

March 2023

Br J Dermatol

Roflumilast cream for plaque psoriasis with facial/neck & intertriginous involvement (post hoc)
Read More

February 2023

J Drugs Dermatol

Safety & efficacy of roflumilast cream 0.15% and 0.05% in atopic dermatitis (phase 2 POC)
Read More

November 2022

Am J Clin Dermatol

Pharmacokinetics of roflumilast cream in chronic plaque psoriasis: data from phase I–III studies
Read More

November 2022

Am J Clin Dermatol

Effect of roflumilast cream (ARQ-151) on itch & itch-related sleep loss in adults with plaque psoriasis (phase 2b)
Read More

October 2022

JAMA

Effect of Roflumilast Cream vs Vehicle Cream on Chronic Plaque Psoriasis The DERMIS-1 and DERMIS-2 Randomized Clinical Trials
Read More

September 2022

EADV 2022

Efficacy and safety of roflumilast foam 0.3% in patients with seborrheic dermatitis in a phase 3 trial
Read More

September 2022

EADV 2022

Long-term Safety and Efficacy of Roflumilast Foam 0.3% in Patients With Seborrheic Dermatitis in a 24–52-week, Open-label Phase 2 Trial
Read More

September 2022

EADV 2022

Efficacy and Tolerability of Roflumilast Cream 0.3% in Patients With Chronic Plaque Psoriasis Involvement on the Face, Intertriginous, or Genital Areas: Pooled Results from Phase 3 Trials (DERMIS-1 and DERMIS-2)
Read More

September 2022

EADV 2022

Efficacy and Safety by Race and Ethnicity in a Randomized, Double-blind, Vehicle-Controlled, Phase 2a Study Evaluating Once-Daily Roflumilast Foam 0.3% in Patients With Seborrheic Dermatitis
Read More

April 2022

AMCP 2022

Effects of Roflumilast Cream on Patient Burden and Work Productivity in Patients With Psoriasis
Read More

April 2022

AAD 2022

Pooled Efficacy and Safety Results From the DERMIS-1 and DERMIS-2 Phase 3 Trials of Once-Daily Roflumilast Cream 0.3% by Baseline Body Surface Area
Read More

Meaningful innovation at a glance.

Download our corporate fact sheet.

Download
You are leaving Arcutis.com.

This link will send you to a site maintained by an independent third party.
Arcutis is not responsible for the content on that site.

Cancel Continue